An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy

BACKGROUND: For lung adenocarcinoma (LUAD) patients receiving platinum-based adjuvant chemotherapy (ACT), predictive signatures extracted from survival data solely are not directly associated with platinum response. Another limitation of reported signatures, commonly based on risk scores summarised...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Qi, Lishuang, Li, Yang, Qin, Yuan, Shi, Gengen, Li, Tianhao, Wang, Jiasheng, Chen, Libin, Gu, Yunyan, Zhao, Wenyuan, Guo, Zheng
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2016
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5155365/
https://ncbi.nlm.nih.gov/pubmed/27855439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.370
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars